Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris.
OBJECTIVE
To evaluate the relationship between thiopurine methyltransferase (TPMT) activity and the safety and efficacy of azathioprine sodium in the treatment of pemphigus vulgaris.


METHODS
Cross-sectional study.


METHODS
Referral university hospital for autoimmune blistering diseases.


METHODS
One hundred thirty-nine patients with pemphigus vulgaris treated with azathioprine. Intervention The TPMT activity in red blood cells was measured using high-performance liquid chromatography. Main Outcome Measure Severe adverse effects were defined as those judged serious enough that azathioprine therapy be discontinued in 139 patients treated with azathioprine. To evaluate the relationship of clinical response and TPMT concentration in 52 patients who had been treated with a combination of prednisolone and azathioprine only for at least 1 year were included in the study, and the clinical response was considered favorable if there was no recurrence of pemphigus vulgaris in the first year of treatment.


RESULTS
The median activity of TPMT was 44.7 ng/mL/h (interquartile range, 28.7 ng/mL/h). Eleven patients (7.9%) had low TPMT activity (TPMT-HL), 127 patients (91.4%) had normal TPMT activity (TPMT-HH), and 1 patient (0.7%) had supranormal enzyme activity; TPMT activity was noted in all patients. Serious adverse effects occurred in 14 patients (10.1%). There was no relationship between development of adverse effects and TPMT activity (P = .29). Eleven patients with low TMPT activity had been treated with azathioprine for a mean (SD) of 10.2 (4.1) months. Only 1 patient exhibited serious adverse effects. The TPMT enzyme activity was not different in 28 patients with unfavorable clinical response compared with 24 patients with favorable clinical response (P = .09). Conclusion Larger prospective studies are needed to determine the clinical relevance of TPMT activity and to determine accurate azathioprine dosing guidelines based on TPMT activity.
Firooz
Alireza
A
Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, Tehran 14166, Iran. firozali@sina.tums.ac.ir
Ghandi
Nargess
N
Hallaji
Zahra
Z
Chams-Davatchi
Cheyda
C
Valikhani
Mahin
M
Karbakhsh Davari
Mozhgan
M
D000328:Adult; D001379:Azathioprine / Q000009:adverse effects* / Q000627:therapeutic use*; D002851:Chromatography, High Pressure Liquid; D003430:Cross-Sectional Studies; D004359:Drug Therapy, Combination; D004912:Erythrocytes / Q000201:enzymology; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008780:Methyltransferases / Q000097:blood*; D008875:Middle Aged; D010392:Pemphigus / Q000097:blood / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use; D016896:Treatment Outcome
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011239:Prednisolone; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D001379:Azathioprine